Impact of physical size on gefitinib efficacy in patients with non-small cell lung cancer harboring EGFR mutations

Eiki Ichihara, Katsuyuki Hotta, Nagio Takigawa, Kenichiro Kudo, Yuka Kato, Yoshihiro Honda, Hiromi Hayakawa, Daisuke Minami, Akiko Sato, Masahiro Tabata, Mitsune Tanimoto, Katsuyuki Kiura

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Gefitinib is an essential drug for the treatment of non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) gene mutations. The approved dosage is 250mg/body/day without adjustment for physical size such as body surface area (BSA), and the impact of physical size on the efficacy of gefitinib has not been evaluated. Here, we sought to clarify this issue using a retrospective cohort. We reviewed the medical records of patients with consecutive advanced NSCLC harboring EGFR mutations who underwent gefitinib monotherapy at Okayama University Hospital. In total, 101 patients were included in this study, and the median BSA in this cohort was 1.5m2. The median progression-free survival (PFS) of the patients with higher BSA (≥1.5m2) was significantly worse than that of those with lower BSA (2) (10.4 vs. 18.0 months; p=0.019, log-rank test). Multivariate analysis also showed a significant impact of BSA on PFS (hazards ratio, 2.34; 95% confidence interval, 1.78-2.89; p=0.002). By contrast, no significant association between BSA and PFS was observed in those undergoing cytotoxic chemotherapy (4.0 vs. 5.1 months; p=0.989, log-rank test), suggesting that BSA is a predictive, rather than a prognostic, marker for gefitinib therapy in EGFR-mutated NSCLC. In conclusion, BSA affected PFS in patients with EGFR-mutated NSCLC who underwent gefitinib monotherapy, suggesting the need for appraisal of BSA-based dose adjustment, even for this molecular target-based therapy.

Original languageEnglish
Pages (from-to)435-439
Number of pages5
JournalLung Cancer
Volume81
Issue number3
DOIs
Publication statusPublished - Sep 2013

Fingerprint

Body Surface Area
Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Mutation
Disease-Free Survival
Essential Drugs
erbB-1 Genes
gefitinib
Medical Records
Therapeutics
Multivariate Analysis
Confidence Intervals
Drug Therapy

Keywords

  • Body surface area
  • Epidermal growth factor receptor mutation
  • Gefitinib
  • Non-small cell lung cancer
  • Progression free survival
  • Tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Impact of physical size on gefitinib efficacy in patients with non-small cell lung cancer harboring EGFR mutations. / Ichihara, Eiki; Hotta, Katsuyuki; Takigawa, Nagio; Kudo, Kenichiro; Kato, Yuka; Honda, Yoshihiro; Hayakawa, Hiromi; Minami, Daisuke; Sato, Akiko; Tabata, Masahiro; Tanimoto, Mitsune; Kiura, Katsuyuki.

In: Lung Cancer, Vol. 81, No. 3, 09.2013, p. 435-439.

Research output: Contribution to journalArticle

Ichihara, Eiki ; Hotta, Katsuyuki ; Takigawa, Nagio ; Kudo, Kenichiro ; Kato, Yuka ; Honda, Yoshihiro ; Hayakawa, Hiromi ; Minami, Daisuke ; Sato, Akiko ; Tabata, Masahiro ; Tanimoto, Mitsune ; Kiura, Katsuyuki. / Impact of physical size on gefitinib efficacy in patients with non-small cell lung cancer harboring EGFR mutations. In: Lung Cancer. 2013 ; Vol. 81, No. 3. pp. 435-439.
@article{83670bd412f849efb613274a6b4b1313,
title = "Impact of physical size on gefitinib efficacy in patients with non-small cell lung cancer harboring EGFR mutations",
abstract = "Gefitinib is an essential drug for the treatment of non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) gene mutations. The approved dosage is 250mg/body/day without adjustment for physical size such as body surface area (BSA), and the impact of physical size on the efficacy of gefitinib has not been evaluated. Here, we sought to clarify this issue using a retrospective cohort. We reviewed the medical records of patients with consecutive advanced NSCLC harboring EGFR mutations who underwent gefitinib monotherapy at Okayama University Hospital. In total, 101 patients were included in this study, and the median BSA in this cohort was 1.5m2. The median progression-free survival (PFS) of the patients with higher BSA (≥1.5m2) was significantly worse than that of those with lower BSA (2) (10.4 vs. 18.0 months; p=0.019, log-rank test). Multivariate analysis also showed a significant impact of BSA on PFS (hazards ratio, 2.34; 95{\%} confidence interval, 1.78-2.89; p=0.002). By contrast, no significant association between BSA and PFS was observed in those undergoing cytotoxic chemotherapy (4.0 vs. 5.1 months; p=0.989, log-rank test), suggesting that BSA is a predictive, rather than a prognostic, marker for gefitinib therapy in EGFR-mutated NSCLC. In conclusion, BSA affected PFS in patients with EGFR-mutated NSCLC who underwent gefitinib monotherapy, suggesting the need for appraisal of BSA-based dose adjustment, even for this molecular target-based therapy.",
keywords = "Body surface area, Epidermal growth factor receptor mutation, Gefitinib, Non-small cell lung cancer, Progression free survival, Tyrosine kinase inhibitor",
author = "Eiki Ichihara and Katsuyuki Hotta and Nagio Takigawa and Kenichiro Kudo and Yuka Kato and Yoshihiro Honda and Hiromi Hayakawa and Daisuke Minami and Akiko Sato and Masahiro Tabata and Mitsune Tanimoto and Katsuyuki Kiura",
year = "2013",
month = "9",
doi = "10.1016/j.lungcan.2013.05.021",
language = "English",
volume = "81",
pages = "435--439",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Impact of physical size on gefitinib efficacy in patients with non-small cell lung cancer harboring EGFR mutations

AU - Ichihara, Eiki

AU - Hotta, Katsuyuki

AU - Takigawa, Nagio

AU - Kudo, Kenichiro

AU - Kato, Yuka

AU - Honda, Yoshihiro

AU - Hayakawa, Hiromi

AU - Minami, Daisuke

AU - Sato, Akiko

AU - Tabata, Masahiro

AU - Tanimoto, Mitsune

AU - Kiura, Katsuyuki

PY - 2013/9

Y1 - 2013/9

N2 - Gefitinib is an essential drug for the treatment of non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) gene mutations. The approved dosage is 250mg/body/day without adjustment for physical size such as body surface area (BSA), and the impact of physical size on the efficacy of gefitinib has not been evaluated. Here, we sought to clarify this issue using a retrospective cohort. We reviewed the medical records of patients with consecutive advanced NSCLC harboring EGFR mutations who underwent gefitinib monotherapy at Okayama University Hospital. In total, 101 patients were included in this study, and the median BSA in this cohort was 1.5m2. The median progression-free survival (PFS) of the patients with higher BSA (≥1.5m2) was significantly worse than that of those with lower BSA (2) (10.4 vs. 18.0 months; p=0.019, log-rank test). Multivariate analysis also showed a significant impact of BSA on PFS (hazards ratio, 2.34; 95% confidence interval, 1.78-2.89; p=0.002). By contrast, no significant association between BSA and PFS was observed in those undergoing cytotoxic chemotherapy (4.0 vs. 5.1 months; p=0.989, log-rank test), suggesting that BSA is a predictive, rather than a prognostic, marker for gefitinib therapy in EGFR-mutated NSCLC. In conclusion, BSA affected PFS in patients with EGFR-mutated NSCLC who underwent gefitinib monotherapy, suggesting the need for appraisal of BSA-based dose adjustment, even for this molecular target-based therapy.

AB - Gefitinib is an essential drug for the treatment of non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) gene mutations. The approved dosage is 250mg/body/day without adjustment for physical size such as body surface area (BSA), and the impact of physical size on the efficacy of gefitinib has not been evaluated. Here, we sought to clarify this issue using a retrospective cohort. We reviewed the medical records of patients with consecutive advanced NSCLC harboring EGFR mutations who underwent gefitinib monotherapy at Okayama University Hospital. In total, 101 patients were included in this study, and the median BSA in this cohort was 1.5m2. The median progression-free survival (PFS) of the patients with higher BSA (≥1.5m2) was significantly worse than that of those with lower BSA (2) (10.4 vs. 18.0 months; p=0.019, log-rank test). Multivariate analysis also showed a significant impact of BSA on PFS (hazards ratio, 2.34; 95% confidence interval, 1.78-2.89; p=0.002). By contrast, no significant association between BSA and PFS was observed in those undergoing cytotoxic chemotherapy (4.0 vs. 5.1 months; p=0.989, log-rank test), suggesting that BSA is a predictive, rather than a prognostic, marker for gefitinib therapy in EGFR-mutated NSCLC. In conclusion, BSA affected PFS in patients with EGFR-mutated NSCLC who underwent gefitinib monotherapy, suggesting the need for appraisal of BSA-based dose adjustment, even for this molecular target-based therapy.

KW - Body surface area

KW - Epidermal growth factor receptor mutation

KW - Gefitinib

KW - Non-small cell lung cancer

KW - Progression free survival

KW - Tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=84881665232&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881665232&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2013.05.021

DO - 10.1016/j.lungcan.2013.05.021

M3 - Article

VL - 81

SP - 435

EP - 439

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 3

ER -